JOHNSON & JOHNSON

JNJ · XNYS

CIK 200406fmd_0NTEAXK4F83RXXAN3PNEWN6K3QManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2007 to Sep 27, 2026, 75 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	71,890	76,450	81,581	82,059	82,584	78,740	79,990	85,159	88,821	94,193
Cost of revenue	21,789	25,439	27,091	27,556	28,427	23,402	24,596	26,553	27,471	30,256
Gross profit	50,101	51,011	54,490	54,503	54,157	55,338	55,394	58,606	61,350	63,937
Research and development	9,143	10,594	10,775	11,355	12,159	0	0	483	1,841	109
Selling, general and administrative	20,067	21,520	22,540	22,178	22,084	20,118	20,246	21,512	22,869	23,676
Operating income	–	–	–	–	–	–	–	–	–	–
Interest expense	726	934	1,005	318	201	183	276	772	755	971
Interest and investment income	368	385	611	357	111	53	490	1,261	1,332	1,056
Other non-operating income (expense)	(210)	42	(1,405)	(2,525)	(2,899)	(526)	(810)	(6,634)	(4,694)	7,209
Income before taxes	19,803	17,673	17,999	17,328	16,497	19,178	19,359	15,062	16,687	32,581
Income tax expense	3,263	16,373	2,702	2,209	1,783	1,377	2,989	1,736	2,621	5,777
Net income from continuing operations	16,540	1,300	15,297	15,119	14,714	17,801	16,370	13,326	14,066	26,804
Net income	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153	14,066	26,804